Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,174 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: stem cell infusion Clear all

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS, Inherited Bone Marrow Failure Syndrome, Myeloid Neoplasm, Aml
Interventions: Decitabine, Filgrastim; Drug
Lead sponsor: Franziska Wachter; Other
Eligibility: 1 Year to 39 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-Hodgkins Lymphoma
Interventions: Rituximab; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Kansas City, Kansas

Conditions: Renal Failure
Interventions: Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lymphoma
Interventions: filgrastim, carboplatin, carmustine, cyclophosphamide, cytarabine, etoposide, ifosfamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 120 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: 131I-MIBG, Vincristine, Irinotecan, Vorinostat; Radiation · Drug
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 2 Years to 30 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Cyclophosphamide, Melphalan, Fludarabine, Bortezomide, Leukapheresis, Interleukin, Infusion #1, Leukapheresis #2, Infusion #2, Auto Graft; Drug · Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Post-Concussion Syndrome
Interventions: 50 Adipose Derived Stem Cell Infusion, 150 Adipose Derived Stem Cell Infusion, 300 Adipose Derived Stem Cell Infusion, Placebo Infusion; Drug
Lead sponsor: American CryoStem Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: La Mesa, California

Conditions: Lymphoma
Interventions: Vorinostat, Gemcitabine, Busulfan, Melphalan, Stem Cell Infusion, Rituximab, G-CSF, Palifermin, Dexamethasone acetate; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematologic Malignancy, Refractory Lymphoma
Interventions: Radiotherapy; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral T-Cell Lymphoma
Interventions: Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection, Granulocyte-colony stimulating factor (G-CSF), Pegfilgrastim, Cyclophosphamide, Vincristine, Leucovorin, Methotrexate, Doxorubicin Hydrochloride, Cytarabine, Etoposide, Carmustine, Denileukin diftitox; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sickle Cell Disease
Interventions: single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a; Biological
Lead sponsor: David Williams; Other
Eligibility: 3 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Multiple Myeloma, Plasma Cell Myeloma
Interventions: filgrastim, cyclophosphamide, dexamethasone, melphalan, thalidomide, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 35
States / cities: Little Rock, Arkansas • Sacramento, California • Boise, Idaho + 19 more

Conditions: Lumbar Degenerative Disc Disease
Interventions: BMAC & Allograft, Iliac Crest Bone Graft; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 3
States / cities: New York, New York • Westbury, New York

Conditions: Leukemia, Lymphoma, Myeloma
Interventions: Rituximab, Cyclophosphamide, Fludarabine, Mesna, Radiation Treatment, Stem Cell Transplantation (SCT), Sirolimus, Anti-third Party Cytolytic T-lymphocytes (CTL); Drug · Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Mesenchymal Stem Cells (MSCs), Placebo Infusion (Plasmalyte A with 0.5% human serum albumin); Biological · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Multiple Myeloma
Interventions: Tremelimumab, Durvalumab, Prevnar-13, Melphalan; Drug · Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia
Interventions: Blinatumomab, Hematopoietic Cell Transplantation; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: filgrastim, busulfan, melphalan, thiotepa, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Granulomatous Disease
Interventions: Sirolimus, Cyclophosphamide, Alemtuzumab, Busulfan, Pheripheral blood stem cells, Emapalumab-Izsg, Tociluzumab, Total Body Irradiation; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cerebral Palsy
Interventions: umbilical cord blood (hUCB) cells, Saline Infusion (Placebo), bone marrow derived mononuclear cells (BMMNCs); Biological · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 10 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma (Skin)
Interventions: gp100 antigen, incomplete Freund's adjuvant, keyhole limpet hemocyanin, fludarabine phosphate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Providence Cancer Center, Earle A. Chiles Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Newly Diagnosed Multiple Myeloma (NDMM)
Interventions: AZD0120, Cyclophosphamide, Fludarabine, Melphalan (part of ASCT), Lenalidomide; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2039
U.S. locations: 46
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 37 more

Conditions: Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
Interventions: Total Body Irradiation with Fludarabine in UCB Transplants; Procedure
Lead sponsor: Duke University; Other
Eligibility: 14 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Myeloma
Interventions: Plinabulin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma

Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Radiation Post-CAR T in Refractory Lymphoma

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Gene Transfer for Sickle Cell Disease

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Prospective Study of Thoracolumbar Spinal Fusion Graft

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)